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Type 1 vanilloid receptors (VR1 ) have been identified recently in the brain, in which they serve as yet primarily undetermined purposes.
The endocannabinoid anandamide (AEA) and some of its oxidative metabolites are ligands for VR1 , and AEA has been shown to afford
protection against ouabain-induced in vivo excitotoxicity, in a manner that is only in part dependent on the type 1 cannabinoid (CB1 )
receptor. In the present study, we assessed whether VR1 is involved in neuroprotection by AEA and by arvanil, a hydrolysis-stable AEA
analog that is a ligand for both VR1 and CB1. Furthermore, we assessed the putative involvement of lipoxygenase metabolites of AEA in
conveying neuroprotection. Using HPLC and gas chromatography/mass spectroscopy, we demonstrated that rat brain and blood cells
converted AEA into 12-hydroxy-N-arachidoylethanolamine (12-HAEA) and 15-hydroxy-N-arachidonoylethanolamine (15-HAEA) and
that this conversion was blocked by addition of the lipoxygenase inhibitor nordihydroguaiaretic acid. Using magnetic resonance imaging
we show the following: (1) pretreatment with the reduced 12-lipoxygenase metabolite of AEA, 12-HAEA, attenuated cytotoxic edema
formation in a CB1 receptor-independent manner in the acute phase after intracranial injection of the Na
/K -ATPase inhibitor
ouabain; (2) the reduced 15-lipoxygenase metabolite, 15-HAEA, enhanced the neuroprotective effect of AEA in the acute phase; (3)
modulation of VR1 , as tested using arvanil, the VR1 agonist capsaicin, and the antagonist capsazepine, leads to neuroprotective effects in
this model, and arvanil is a potent neuroprotectant, acting at both CB1 and VR1 ; and (4) the in vivo neuroprotective effects of AEA are
mediated by CB1 but not by lipoxygenase metabolites or VR1.
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Introduction
The eicosanoid anandamide [N-arachidonoylethanolamine
(AEA)] mimics the pharmacological actions of 9-tetrahy-
drocannabinol (THC), the main psychoactive compound in
marijuana, and was the first endocannabinoid to be discovered
(Devane et al., 1992) (for review, see Di Marzo et al., 1998). THC,
AEA, and the other endocannabinoid 2-arachidonoylglycerol
(Mechoulam et al., 1995) exert neuroprotection in several mod-
els of neuronal injury (Nagayama et al., 1999; Panikashvili et al.,
2001; van der Stelt et al., 2001a,b) (for review, see Mechoulam et
al., 2002), and mice with a defective type 1 cannabinoid (CB1)
receptor gene appear to be more susceptible to injury after stroke
(Parmentier-Batteur et al., 2002). At variance with the protection
observed with AEA in the late phase (7 d) after induction of
excitotoxicity (van der Stelt et al., 2001b) and unlike the effect of
THC (van der Stelt et al., 2001a), the protection afforded by the
endocannabinoid in the early phase (15 min) was not sensitive to
the CB1 receptor antagonist SR141716A. This suggests that AEA
or its metabolites may convey neuroprotection via other molec-
ular targets in addition to the CB1 receptor. Indeed, both AEA
and 2-arachidonoylglycerol exert, in vitro, neuroprotective ef-
fects that are not always attenuated by a cannabinoid CB1 antag-
onist (Sinor et al., 2000).
AEA is also a full agonist at the type 1 vanilloid receptor (VR1)
(Zygmunt et al., 1999; Smart et al., 2000), which is the target of
capsaicin, the pungent principle in hot chili peppers. The VR1 is a
nonselective cation channel expressed in sensory fibers, in which
it acts as a ligand-, proton-, and heat-activated integrator of no-
ciceptive stimuli (Szallasi and Blumberg, 1999) and whose pres-
ence in the brain has been also established (Mezey et al., 2000;
Sanchez et al., 2001; Szabo et al., 2002). Because, in the CNS, VR1
is unlikely to be gated by noxious heat and low pH as in the
peripheral nervous system, endogenous ligands for this receptor,
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such as AEA, N-arachidonoyldopamine (Huang et al., 2002), and
lipoxygenase products of both arachidonic acid (AA) (Hwang et
al., 2000) and AEA (Craib et al., 2001) might exist in the brain.
These compounds, once produced under inflammatory condi-
tions, might activate VR1 with subsequent calcium influx (Szal-
lasi and Blumberg, 1999), glutamate release (Marinelli et al.,
2002), and substantial contribution to neuronal excitotoxicity.
Conversely, exogenous compounds capable of quickly desensitiz-
ing VR1, such as many VR1 agonists, including AEA, might exert
neuroprotective actions by preventing VR1 activation by endog-
enous stimuli, and this mechanism might underlie the previously
reported anticonvulsant effect of capsaicin (Dib and Falchi,
1996).
In the current study, we investigated the role of VR1 and li-
poxygenase products in the neuroprotection elicited in vivo by
AEA. To this aim, we assessed the following: (1) the formation of
lipoxygenase metabolites of AEA in rat blood and brain; (2) their
effects in our in vivo model of neurodegeneration; (3) the effect of
VR1 stimulation using capsaicin and arvanil, a “hybrid” VR1/CB1
agonist; and (4) the effects of the VR1 antagonist capsazepine and
of the lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA)
on AEA-induced neuroprotection.
Materials and Methods
Brain tissue preparation. Male Wistar (200 –300 gm) rats were killed by an
overdose of pentobarbital and decapitated, after which their forebrains
were rapidly isolated. Blood was collected in PBS containing Na3-citrate
(0.15 M). Some of the animals were transcardially perfused with PBS.
Brains were minced with a razor blade and collected in ice-cold PBS (10
gm of tissue/100 ml of PBS).
Anandamide incubations. Brain tissue or blood cells were preincubated
at 37°C for 10 min before a 20 min incubation with ionophore A23187
(10 M), Ca 2 (1 mM), and 40 M substrate. In the case of AEA, 100 M
PMSF was included in the incubation mixture. Reaction was terminated
by addition of precooled chloroform/methanol (2:1) to extract lipids
according to the Bligh and Dyer method (Bligh and Dyer, 1959).
HPLC analysis and product identification. Reversed-phase HPLC chro-
matograms were obtained using a Hewlett-Packard (Palo Alto, CA)
HP1090 liquid chromatograph equipped with an HP1040A diode array
detector with a detection limit 40 pmol (for conjugated dienes) and
with an HP79994A analytical workstation. HPLC nalysis was performed
on a Cosmosil 5C18-AR (5 mm; 250  4 mm inner diameter; Nacalai
Tesque, Kyoto, Japan) column, using a methanol/water mixture (80:20)
as the eluent at a flow rate of 1 ml/min. Compounds were collected and
dried under N2 flow and silylated with a bis(trimethylsilyl)fluoro-
acetamide for 15 min at room temperature. Gas liquid chromatography/
mass spectroscopy (GC/MS) analysis was performed by injecting the
samples on column (25 m HT-5 SGE column, 0.1 mm film thickness;
SGE, Austin, TX). The column temperature was held at 70°C for 3 min
and then allowed to rise 240°C at 40°C/min, followed by an increase of
16°C/min up to 330°C. Mass spectrometry was performed with a Fisons
Instruments MD 800 mass detector. Mass spectra were recorded under
electron impact with an ionization energy of 70 eV.
Animal model. Neonatal Wistar rats (U:Wu/Cpb; 7– 8 d old) were
anesthetized with ether and immobilized in a stereotaxic frame. A small
burr hole was drilled in the cranium over the left hemisphere, 2.5 mm
lateral of bregma. A 1 l syringe was lowered into the left striatum to a
depth of 4.0 mm. Ouabain (0.5 l, 1 mM; Sigma-Aldrich, Zwijndrecht,
The Netherlands) was injected at a rate of 0.125 l/min using a micro-
drive. After injection, the needle was left in situ for 2 min to avoid leakage
of injection fluid from the needle tract. Body temperature was main-
tained at 37°C using a water-filled heating pad and an infrared heating
lamp. Animals, needed for magnetic resonance imaging (MRI) study,
were then positioned in the magnet, and anesthesia was continued using
a mixture of halothane (0.4 –1%) in N2O–O2.
Pharmacological treatments. Arvanil was synthesized as described pre-
viously (Melck et al., 1999). 12-Hydroxy-N-arachidoylethanolamine
(12-HAEA) and 15-hydroxy-N-arachidonoylethanolamine (15-HAEA)
were synthesized, purified, and characterized as described previously
(van Zadelhoff et al., 1998). AEA was obtained from Biomol (Heerh-
ugowaard, The Netherlands), SR141716A from Sanofi Recherche
(Montpellier, France), capsaicin and capsazepine from Tocris (Köln,
Germany), and NDGA from Sigma-Aldrich. Animals used in the MRI
study were treated intraperitoneally with arvanil (0.1 or 1 mg/kg; n  5
and n  6, respectively), arvanil (1 mg/kg) plus SR141716A (1 and 3
mg/kg; n  5 and n  4, respectively), arvanil (1 mg/kg) plus capsazepine
(5 and 10 mg/kg; n  4 and 10, respectively), capsaicin (1 mg/kg; n  5),
AEA (1 mg/kg) plus 15-HAEA (7 mg/kg; n  7), NDGA (10 mg/kg; n 
6) 5 min before AEA (10 mg/kg), NDGA (10 mg/kg; n  6), AEA (10
mg/kg) plus capsazepine (10 mg/kg; n  5), capsazepine (10 mg/kg; n 
5), 12-HAEA (3 mg/kg; n  6), or 12-HAEA (3 mg/kg) plus SR141716A
(3 mg/kg; n  5). Control animals received vehicle alone (n  16).
15-HEAE was tested at a dose likely to produce a molar ratio with AEA
(7:1) similar to the one previously found in vitro to inhibit AEA degra-
dation (van der Stelt et al., 2002b). Because 12-HAEA and 15-HAEA are
only very weak agonists at VR1 and 15-HAEA is only a weak ligand at
CB1, we did not test the effect of capsazepine on the two compounds, nor
of SR141716A on 15-HAEA or of 15-HAEA alone (Hwang et al., 2000;
van der Stelt et al., 2002b). Because AEA is a very weak functional agonist
at CB2 receptors (Bayewitch et al., 1995; Gonsiorek et al., 2000) and
arvanil has little if any affinity for these receptors (Melck et al., 1999; Di
Marzo et al., 2002), no experiment with CB2 antagonists were performed.
All drugs were dissolved in 1 ml/kg body weight 18:1:1 v/v PBS/Tween
80/ethanol, 30 min before toxin injection. There was no difference in
body weight and growth rate between any of the groups. The Utrecht
University Animal Experiment Ethical Committee approved all
protocols.
MRI experiments. MRI was performed on a 4.7 T Varian horizontal
bore spectrometer. Resonance frequency excitation and signal detection
were accomplished by means of a Helmholtz volume coil (9 cm diame-
ter) and an inductively coupled surface coil (2 cm diameter), respectively.
A single-scan diffusion-trace MRI-sequence [four b values, 100 –1300
sec/mm 2; repetition time (TR), 3 sec; echo time (TE), 100 msec] was used
to generate quantified images of tissue water trace apparent diffusion
coefficient. Diffusion-trace- and T2-weighted imaging (TE of 18, 40, 62,
and 84 msec; TR of 2 sec; number of transients, 2) were performed in all
animals (2.2  2.2 cm field of view; 64  64 data matrix), starting at t 
15 min after injection on day 0 and were repeated 1 week later. As ex-
pected, at this early time point, no changes in T2-weighted MRI were
detected. Both the T2-weighted and the diffusion-weighted (DW) data-
sets consisted of seven consecutive 1.5-mm-thick slices, with 0 mm slice
gap. To minimize interference at the slice boundaries, slices were ac-
quired in alternating order (1, 3, 5, 7, 2, 4, 6), thus maximizing the time
between excitation of two neighboring slices. For the diffusion-weighted
imaging, we used a double spin-echo pulse sequence with four pairs of
bipolar gradients with specific predetermined signs in each of the three
orthogonal directions as published recently (De Graaf et al., 2001). The
combination of gradient directions leads to cancellation of all off-
diagonal tensor elements, thus effectively measuring the trace of the dif-
fusion tensor. This provides unambiguous and rotationally invariant
apparent diffusion coefficient (ADC) values in one experiment, circum-
venting the need for three separate experiments. For each b value, two
scans were averaged. The total scan time for acquisition of seven slices,
with four b values and two averages, was 17 min.
Data analysis. ADC and T2 maps were generated by monoexponential
fitting using the Interactive Data Language software package. Parametric
images were analyzed in anatomic regions of interest using the Interac-
tive Data Language software package. Pixels in the ipsilateral hemisphere
were considered pathological if their ADC or T2 value differed more than
twice the SD of the mean value in the contralateral hemisphere. The
ventricles were segmented out in the average ADC and T2 measurements.
The lesion volume per slice was calculated by multiplying the lesion area
(number of pathological pixels  field-of-view in cm 2/number of points
acquired per image) by the slice thickness. The total lesion volume was
obtained by summation of the lesion volumes for all slices. The absence
of a slice gap makes interpolation of lesion areas between slices unneces-
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sary, reducing systematic errors to within-slice “averaging” of signal in-
tensity. Statistical analysis was performed using SPSS 10.0 (SPSS, Chi-
cago, IL). Differences between groups were analyzed using Student’s t
test; reported p values correspond to two-tailed significance.
Results
Lipoxygenase metabolism of anandamide
Reversed-phase HPLC analyses of the lipid extracts of AEA incu-
bations with rat brain homogenates were performed to deter-
mine whether AEA metabolites were formed. The reversed-phase
HPLC analyses revealed that several products eluted with an ab-
sorption at   236 nm, which were absent in control incuba-
tions without AEA. These peaks were not present when NDGA, a
nonselective lipoxygenase inhibitor, was included in the incuba-
tion (Fig. 1). Two peaks eluted at the same retention times as the
reduced lipoxygenase products of AEA, 15-HAEA (TR of 6.4
min) and 12-HAEA (TR of 7.9 min), respectively. The UV spectra
of these materials demonstrated an absorption maximum at 236
nm and were similar to the spectra of standards of 12-HAEA and
15-HAEA. The peaks were collected, derivatized, and subjected to
GC/MS analysis. The mass spectra confirmed that the peaks elut-
ing at 6.4 and 7.9 min represented 15-HAEA and 12-HAEA, re-
spectively. AEA incubations with brains from rats that were tran-
scardially perfused with PBS before dissection demonstrated a
similar elution profile, although the ratio of 15-HAEA to 12-
HAEA was changed (Fig. 1). This suggested that at least a part of
the oxygenated metabolites, especially 15-HAEA, were produced
by lipoxygenases expressed in blood cells. AEA incubations with
rat blood cells demonstrated that 15-HAEA and 12-HAEA could
be formed (data not shown). The cellular origin of the lipoxygen-
ase activity was not investigated.
Role of lipoxygenase metabolites in neuroprotection after
anandamide treatment
We wanted to investigate whether the lipoxygenase metabolites
of AEA detected here might mediate the non-CB1-mediated
acute neuroprotective effect of AEA in our rat model of in vivo
excitotoxicity (van der Stelt et al., 2001b; Veldhuis et al., 2003). In
these experiments, we used reduced lipoxygenase products of
AEA because the hydroperoxy derivatives will be rapidly de-
graded in vivo. In our model, excitotoxicity is induced by phar-
macologically inhibiting the Na/K-ATPase using ouabain.
The resulting acute cellular swelling (i.e., cytotoxic edema) is
conveniently monitored using diffusion-weighted MRI. ADC
maps of tissue water, calculated from DW-MRI datasets, showed
hypointense regions with reduced ADC values (0.64  0.006 
103 mm 2/sec) in the ipsilateral hemisphere of all animals. In the
contralateral hemisphere, normal ADC values (1.13  0.01 
103 mm 2/sec) were measured (Fig. 2A). We showed previously
that administration of AEA itself dose-dependently reduces le-
sion volume in this model (van der Stelt et al., 2001b). The re-
duced 12-lipoxygenase metabolite of AEA, 12-HAEA, attenuated
the volume of cytotoxic edematous tissue in the acute phase after
injection of ouabain ( p  0.05) (Figs. 2A, 3). The CB1 antagonist
SR141716A was unable to block this effect, indicating that the
CB1 receptor was not involved in the protection afforded by 12-
HAEA (Figs. 2A, 3). The reduced 15-lipoxygenase metabolite of
AEA, 15-HAEA [which was shown previously to be only a weak
ligand at CB1 but to inhibit the enzymatic hydrolysis of AEA (van
der Stelt et al., 2002b)], enhanced the protection afforded by a
low dose (1 mg/kg) of AEA [from 37.2 mm 3 (van der Stelt et al.,
2001b) to 26.6 mm 3 ( p  0.05); (Figs. 2A, 3)]. T2 maps calcu-
lated from T2-weighted images acquired 7 d later showed normal
T2 values (71.9  0.04 msec) in the contralateral hemisphere of
all animals. The ouabain-injected hemisphere showed hypoin-
tensities and hyperintensities (Fig. 2B). Both types of T2 abnor-
malities indicate pathological change. Hyperintensities correlate
to regions of vasogenic edema and tissue loss, whereas hypoin-
tensities correspond to regions displaying reactive gliosis
(Veldhuis et al., 2003). Calculation of total lesion volumes based
on both hyperintensities and hypointensities indicated that nei-
ther the protection afforded by 12-HAEA nor the effect of 15-
HAEA lasted until day 7 (Figs. 2B, 3). The dose of 12-HAEA
tested significantly reduced lesion volume in the acute phase,
Figure 1. Reversed-phase HPLC profiles (  236 nm) of lipid extracts of anandamide
incubations with rat brain homogenates using a C18-column with methanol/water (80:20 v/v)
as eluent. Top trace, Anandamide incubation with rat brain and NDGA, a nonselective lipoxy-
genase inhibitor. Middle trace, Anandamide incubation with nonperfused rat brain. Bottom
trace, Anandamide incubation with PBS perfused rat brain. a.u., Arbitrary units.
Figure 2. A, Typical parametric ADC maps of rat brain, calculated from diffusion-weighted
MRI data acquired 15 min after ouabain injection. B, Parametric T2 maps of the corresponding
slices of the same animals, calculated from T2-weighted MRI data acquired 1 week later. The
treatments are as follows: I, vehicle; II, AEA (1 mg/kg) plus 15-HAEA; III, 12-HAEA; IV, 12-HAEA
plus SR141716A; V, capsazepine; VI, AEA (10 mg/kg) plus capsazepine; VII, NDGA; and VIII, AEA
(10 mg/kg) plus NDGA.
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obviating the need to use a higher dose at that this time point. In
the late phase, higher doses of this compound were not investi-
gated because the neuroprotective effect of AEA in this phase is
blocked by SR141716A.
These data might suggest that the SR141716A-insensitive,
early neuroprotective effect observed previously with AEA in the
same in vivo model (van der Stelt et al., 2001b) may have been
attributable to the formation of 12-HAEA and 15-HAEA. To test
this hypothesis, the nonselective lipoxygenase inhibitor NDGA
was injected 5 min before AEA. NDGA did not reverse the AEA-
induced reduction in lesion volume (Figs. 2A, 3). In contrast,
pretreatment of NDGA enhanced the neuroprotective effect of
AEA ( p  0.05) (Figs. 2A, 3), resulting in a 51% smaller lesion
volume compared with control animals ( p  0.05) (Figs. 2A, 3).
Effects of VR1 modulation on
ouabain-induced neurodegeneration
To investigate the possible involvement of VR1 in AEA-induced
neuroprotection, we performed three types of experiments. First,
we tested the neuroprotective effect of arvanil, a synthetic AEA
analog, which is metabolically more stable than AEA and acti-
vates both CB1 and, more potently, VR1 receptors but not CB2
receptors (Melck et al., 1999; Di Marzo et al., 2001b). Next, we
tested the effect of capsaicin, a selective VR1 agonist. And finally,
we tested the effect of the VR1 antagonist capsazepine on AEA-
induced neuroprotection.
Unlike THC, AEA, and 12-HAEA, arvanil (1 mg/kg) did not
reduce lesion size on DW-MRI in the acute phase after injection
of ouabain (38  4.2 mm 3; p  0.05 vs control) (data not
shown), although it was dose-dependently effective at 7 d (Figs. 4,
5). This effect was mimicked by capsaicin at 1 mg/kg. Notewor-
thy, arvanil was more potent than AEA, capsaicin, and THC after
7 d. The 1 mg/kg dose was the highest tolerated dose of capsaicin
for neonatal animals. With arvanil, previous data in adult rats (Di
Marzo et al., 2001a) and mice (Di Marzo et al., 2000), obtained
after intraperitoneal or intravenous administrations of 10 mg/kg
of the substance, respectively, showed that arvanil is much better
tolerated and less toxic than capsaicin (whose highest tolerated
dose was 1 mg/kg in both cases).
To investigate which receptor between CB1 and VR1 mediates
arvanil-induced neuroprotection in the late phase, the CB1 recep-
tor antagonist SR141716A or the VR1 antagonist capsazepine
were coinjected with arvanil (1 mg/kg) into neonatal rats.
SR141716A dose-dependently reduced the neuroprotective effect
of arvanil, suggesting the involvement of CB1 receptors. Interest-
Figure 3. Lesion volumes as determined from ADC maps on day 0 and T2 maps on day 7. The
effects of several combinations of AEA, AEA metabolites, CB1 and VR1 antagonists, and a lipoxy-
genase inhibitor on lesion volume are shown. For comparison, the effect of AEA alone is also
shown. This effect was determined in a previous study (van der Stelt et al., 2001b). Error bars
represent means  SE. *p  0.05 versus control; §p  0.05 for AEA plus NDGA versus AEA
alone. See legend to Figure 2 for all of the doses. CAPSA, Capsazepine (10 mg/kg).
Figure 4. Typical parametric T2 maps calculated from T2-weighted MRI data acquired 7 d
after injection of ouabain. The treatments are as follows: A, vehicle; B, arvanil (0.1 mg/kg); C,
arvanil (1 mg/kg); D, arvanil (1 mg/kg) plus SR141716A (1 mg/kg); E, arvanil (1 mg/kg) plus
SR141716A (3 mg/kg); F, arvanil (1 mg/kg) plus capsazepine (5 mg/kg); G, arvanil (1 mg/kg)
plus capsazepine (10 mg/kg); and H, capsaicin (1 mg/kg).
Figure 5. Lesion volumes as determined from T2 maps acquired 7 d after ouabain injection.
Error bars represent means  SE. *p  0.05 versus control. See legend to Figure 4 for all of the
doses. ARV, Arvanil; CAPSA, capsazepine; SR1, SR141716A.
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ingly, capsazepine was also able to reduce the effect of arvanil,
indicating the possible involvement of VR1 (Figs. 4, 5). Capsaz-
epine at 10 mg/kg did not completely block the effect of arvanil,
but higher doses could not be tested because of the limited solu-
bility of capsazepine in the vehicle solution. However, this dose of
the antagonist was shown previously to be sufficient to entirely
block capsaicin-induced (1 mg/kg) hypolocomotor effects in
adult rats but has no effect on movement impairment induced by
arvanil (1 mg/kg) (Di Marzo et al., 2001a). The finding that arva-
nil and capsaicin were able to attenuate ouabain-induced neuro-
degeneration in neonatal rats in a capsazepine-dependent man-
ner suggests that VR1 stimulation can afford neuroprotection in
this in vivo model. To test whether VR1 could also be involved in
the neuroprotective effects of AEA, capsazepine (10 mg/kg) was
coinjected with AEA (10 mg/kg). However, capsazepine was unable
to block the neuroprotective effect of AEA in both the acute and the
late phase (Figs. 2, 3), arguing against a VR1-mediated mecha-
nism for AEA. Importantly, VR1 antagonism by capsazepine (10
mg/kg) alone also reduced brain injury at 7 d (Figs. 2, 3).
Discussion
The endocannabinoid system is likely to be exploited for the de-
velopment of therapeutics against acute neurodegeneration (Na-
gayama et al., 1999; Panikashvili et al., 2001; van der Stelt et al.,
2001b) (for review, see van der Stelt et al., 2002a). AEA affords
neuroprotection, both in vitro and in vivo, which is only in part
mediated by the CB1 receptor (Sinor et al., 2000; van der Stelt et
al., 2001b). This suggests that other targets of AEA or its metab-
olites may contribute to the observed effects in vivo. In this study,
we assessed a possible role for VR1 and/or lipoxygenase metabo-
lism in the neuroprotection induced by AEA against ouabain-
induced in vivo excitotoxicity. The main findings are as follows:
(1) the 12-lipoxygenase metabolite of AEA, 12-HAEA, attenuated
cytotoxic edema in a CB1 receptor-independent manner in the
acute phase after ouabain injection; (2) the 15-lipoxygenase me-
tabolite, 15-HAEA, enhanced the neuroprotective effect of AEA
in the acute phase; (3) modulation of VR1 leads to neuroprotec-
tive effects in our model, and arvanil is a potent neuroprotectant,
acting at both cannabinoid and vanilloid receptors; and (4) the
acute in vivo neuroprotective effects of AEA are not mediated by
either lipoxygenase metabolism or VR1.
Neuroprotection by lipoxygenase products of anandamide
We showed that rat blood and perfused (blood-free) rat brain
convert exogenous AEA into 12-HAEA and 15-HAEA in an
NDGA-sensitive manner. Our findings are in line with previous
studies using rat brain (Miyamoto et al., 1987) or human blood
(Edgemond et al., 1998). Endogenous lipoxygenase metabolites
of AEA have never been detected, but recent data suggest that
they may mediate some of the actions ascribed to AEA (Kagaya et
al., 2002). For example, the VR1-mediated contractile action of
AEA in guinea pig bronchus may be attributable, at least in part,
to some of its oxygenated metabolites (Craib et al., 2001). Here,
we showed that 12-HAEA was able to mimic the AEA-induced
reduction of cytotoxic edema in the acute phase after ouabain
injection, in a CB1-independent manner. The 12-HAEA-induced
reduction in cellular swelling is likely to occur also independently
of the activation of VR1, because 12-HAEA, unlike its hydroper-
oxy homolog, is not an agonist at VR1 (Hwang et al., 2000).
Furthermore, VR1-stimulation by arvanil did not mimic the re-
duction of cellular swelling in the early phase (see below). 15-
HAEA was able to enhance the neuroprotective effect of AEA.
Because 15-HAEA has been shown to competitively inhibit the
hydrolysis of AEA by FAAH (van der Stelt et al., 2002b), an “en-
tourage” effect might be responsible for the neuroprotection af-
forded by this compound (for a definition of “entourage” effect,
see Mechoulam et al., 1998). However, neither 12-HAEA nor 15-
HAEA afforded long-lasting protection in our model, although, in
contrast to the effect of 12-HAEA, the effect of 15-HAEA almost
reached significance also on day 7 ( p  0.07) (Figs. 2, 3).
At the moment, it is not clear which molecular targets are
responsible for the observed effects of 12-HAEA in the acute
phase. However, pretreatment with the nonselective lipoxygen-
ase inhibitor NDGA did not reverse the AEA-induced reduction
in cytotoxic edema (Fig. 2), and, in contrast, it enhanced the
effect of AEA ( p  0.05). These results indicate that in vivo me-
tabolism catalyzed by lipoxygenases, either directly on AEA or on
AA produced from its hydrolysis (Willoughby et al., 1997; Adams
et al., 1998), is unlikely to contribute to the AEA-induced reduc-
tion of cytotoxic edema. Indeed, application of NDGA alone also
reduced the volume of cytotoxic edema by 25% ( p  0.05) (Fig.
2). This may indicate that endogenous lipoxygenase activity con-
tributes to the neurotoxic events, although an alternative expla-
nation might be that NDGA exerts its protective actions via non-
specific antioxidant activity (Shishido et al., 2001). Altogether,
these data indicate that endogenous lipoxygenase activity does
not contribute to the neuroprotective actions of AEA.
Role of VR1 modulation in neuroprotection by AEA
and arvanil
VR1 is a ligand-gated nonselective cation channel, activation of
which results in nonselective cation influx, Ca 2 influx, mem-
brane depolarization, and glutamate release (Szallasi and Blum-
berg, 1999). During acute neurodegenerative insults, such as
ischemia or trauma, these mechanisms are likely to be detrimen-
tal. In fact, capsaicin treatment is sometimes used to degenerate
peripheral nerves. However, VR1 is easily desensitized by its ago-
nists, and desensitization might lead to neuroprotection if VR1
contributes in any way to the neuronal injury during excitotox-
icity. In fact, capsaicin, the prototypic VR1 agonist, has been
shown previously to inhibit Tween 80-induced convulsions in
vivo (Dib and Falchi, 1996). We report here for the first time a
dose-dependent protection afforded by a hybrid CB1/VR1 ligand,
arvanil, and by capsaicin. The neuroprotective effect of arvanil
was mediated by activation of both CB1 and VR1 receptors and
was more potent than that of capsaicin, AEA, and THC. The
higher efficacy of arvanil may be attributable to a synergistic ac-
tion on two signaling pathways, i.e., (1) stimulation of the CB1
receptor and (2) rapid desensitization of VR1, which might lead
to a reduction in calcium influx and glutamate release. The latter,
tentative mechanism is supported by the following data. (1) VR1
is present in the CNS (Mezey et al., 2000; Sanchez et al., 2001;
Szabo et al., 2002), including in the striatum (Hajos et al., 1988).
(2) In the PNS, desensitization is a standard response of VR1 to
stimulation by exogenously administered agonists (Szallasi and
Blumberg, 1999; Sanchez et al., 2001). Desensitization is known
to take place on time scales relevant to the current experiments
[e.g., within 30 min in sensory nerve terminals of guinea pigs
(Maggi, 1995) or in the rat heart (McLean et al., 2002)]. (3)
Although little is known about the pharmacology of VR1 in the
brain, preliminary observations of repeated capsaicin injections
showed that capsaicin-induced stimulation of CNS neurons
could be blocked by capsaicin pretreatment, suggesting that de-
sensitization may also occur centrally (Hajos et al., 1987). (4)
Desensitization by agonists is prevented by the simultaneous
presence of an antagonist (Jung et al., 1998, 1999; Liu et al., 2001),
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a phenomenon also observed in our study after cotreatment of
arvanil with capsazepine. (5) In the current study, blocking VR1
using capsazepine also afforded protection. Thus, we propose
that both CB1 activation and VR1 desensitization may have con-
tributed to the effect of arvanil. Interestingly, similar results have
been reported previously for the cytostatic treatment of human
breast cancer cells. In those experiments, the effect of AEA was
mediated via CB1 receptors, whereas arvanil exerted a more po-
tent effect that was antagonized by both SR141716A and capsaz-
epine (Melck et al., 1999).
VR1 activation is unlikely to be deleterious to the CNS in
general, but we argue that this might be the case in a setting of
CNS injury. For example, in ischemia, the inflammatory media-
tor bradykinin and the prototypic proinflammatory cytokine tu-
mor necrosis factor- may sensitize VR1 (Nicol et al., 1997; Shin
et al., 2002; Sugiura et al., 2002). Sensitization of VR1 by ligand
binding, mildly acidic pH, or inflammatory mediators may result
in activation of the receptor by temperatures well within the
physiologic range (Tominaga et al., 1998; Vyklicky et al., 1998).
Additionally, VR1 stimulation results in release of substance P,
which is a proinflammatory neuropeptide (Martin et al., 1992;
Annunziata et al., 2002). If these conditions occur during
ouabain-induced excitotoxicity, VR1 desensitization by capsaicin
and arvanil or VR1 antagonism by capsazepine may explain the
neuroprotective effects of these substances.
However, we cannot exclude the possibility that other mech-
anisms may have contributed to the protection afforded by arva-
nil, capsaicin, or capsazepine. For example, both capsaicin and its
dihydroderivate nordihydrocapsiate have similar, potent anti-
inflammatory properties in vivo via nuclear factor-B inhibition,
possibly via a non-VR1-mediated mechanism (Sancho et al.,
2002). Furthermore, capsaicin has been shown to stimulate the
biosynthesis of endocannabinoids (Di Marzo et al., 2001a), which
may afford neuroprotection. Alternatively, the presence in the
CNS of as yet undefined CBn receptors, sensitive to capsaicin,
capsazepine, SR141716A, arvanil, and AEA has been suggested
(Brooks et al., 2002; Hajos and Freund, 2002), which might play a
role in arvanil-mediated neuroprotection.
In our model, we observed non-CB1-dependent effects of
AEA directly after ouabain injection and CB1-dependent effects
after 7 d. In contrast, the neuroprotection by arvanil was evident
at 7 d and was not manifested by a reduction in cytotoxic edema
in the acute phase. These observations, as well as the finding that
the action of AEA was not counteracted by capsazepine, used at a
dose that was effective against a much more potent VR1 agonist
(arvanil), strongly suggest that the neuroprotective effects of the
endocannabinoid are not attributable to VR1 stimulation. There-
fore, it can be concluded that, although the late effect of AEA is
entirely mediated by CB1 receptors, the early action of this com-
pound is attributable to a mechanism yet to be identified.
Conclusions
AEA protects rat brain from ouabain-induced excitotoxicity.
This effect is inhibited by CB1 but not VR1 antagonists and is not
mediated by lipoxygenase metabolites. Arvanil is more potent
than AEA, and both CB1 and VR1 are involved in neuroprotec-
tion after arvanil treatment. We suggest that both VR1 and CB1
receptors might be valuable targets for therapy and drug discov-
ery in protection against brain injury and that arvanil represents
a promising subject for future studies aiming at developing a
monotherapy that targets both receptors simultaneously.
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